NCT03479307View on ClinicalTrials.gov

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

PHASE3CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

April 7, 2018

Primary Completion Date

August 9, 2018

Study Completion Date

August 10, 2018

Conditions
Allergic Conjunctivitis
Interventions
DRUG

Bilastine Ophthalmic Solution 0.6%

1 drop in each eye at 2 separate times during an 8 day period.

DRUG

Ketotifen Ophthalmic Solution 0.025% (Zaditen)

1 drop in each eye at 2 separate times during an 8 day period.

DRUG

Vehicle of Bilastine Ophthalmic Solution

1 drop in each eye at 2 separate times during an 8 day period.

Trial Locations (6)

19134

Philadelphia Eye Associates, Philadelphia

38119

Total Eye Care, P.A., Memphis

45040

Apex Eye, Mason

85032

Cornea Consultants of AZ, Phoenix

90505

East West Eye Institute, Torrance

01810

Andover Eye Associates, Andover

Sponsors

Lead Sponsor

Faes Farma, S.A.
All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Faes Farma, S.A.

INDUSTRY

NCT03479307 - A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. | Biotech Hunter | Biotech Hunter